Showing results (1221-1230 of 1,532) with videos related to
Sort By:
Pageof 154
Evaluation Review|October 25, 2021
Are California's Local Flavored Tobacco Sales Restrictions Effective in Reducing the Retail Availability of Flavored Tobacco Products? A Multicomponent EvaluationElizabeth Andersen-Rodgers, Xueying Zhang, Tam D Vuong, et al.Pain Medicine (Malden, Mass.)|July 19, 2016
Using Patient Perspectives to Inform the Development of a Behavioral Intervention for Chronic Pain in Patients with HIV: A Qualitative StudyJessica S Merlin, Sarah R Young, Mallory O Johnson, et al.International Health|September 18, 2020
The burden of cardiovascular diseases in Ethiopia from 1990 to 2017: evidence from the Global Burden of Disease StudySolomon Ali, Awoke Misganaw, Asnake Worku, et al.Contemporary Clinical Trials Communications|April 27, 2018
Intervention Mapping to develop a Social Cognitive Theory-based intervention for chronic pain tailored to individuals with HIVJessica S Merlin, Sarah R Young, Mallory O Johnson, et al.Biochemistry|September 12, 2009
Characterization of the CHK1 allosteric inhibitor binding siteDarin Vanderpool, Ted O Johnson, Chen Ping, et al.AIDS Care|June 30, 2004
Intricacies and inter-relationships between HIV disclosure and HAART: a qualitative studyR L Klitzman, S B Kirshenbaum, B Dodge, et al.Journal of Neuro-Oncology|March 7, 2020
Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case seriesMallika P Patel, John P Kirkpatrick, Margaret O Johnson, et al.Journal of Musculoskeletal & Neuronal Interactions|June 11, 2016
Four weeks of high- versus low-load resistance training to failure on the rate of torque development, electromechanical delay, and contractile twitch propertiesN Dm Jenkins, T J Housh, S L Buckner, et al.Leukemia Research|August 22, 2016
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)Farhad Ravandi, Ivana Gojo, Mrinal M Patnaik, et al.Neuro-Oncology Practice|March 18, 2024
Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant gliomaKatherine B Peters, Candice Alford, Amy Heltemes, et al.Pageof 154